中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2013年
3期
246-249
,共4页
黄琬玲%周燕斌%黎银焕%黄丽霞%蔡兴东%曾庆理%李少丽
黃琬玲%週燕斌%黎銀煥%黃麗霞%蔡興東%曾慶理%李少麗
황완령%주연빈%려은환%황려하%채흥동%증경리%리소려
非小细胞肺癌%组织因子%高凝状态
非小細胞肺癌%組織因子%高凝狀態
비소세포폐암%조직인자%고응상태
Non-small cell lung cancer%Tissue factor%Hypercoagulation
目的 检测组织因子在非小细胞肺癌(NSCLC)患者血浆中的表达,探讨其与NSCLC患者高凝状态、血栓栓塞性疾病及预后的关系.方法 应用酶联免疫吸附法检测61例NSCLC患者、13例肺部良性疾病患者及14名健康对照者血浆组织因子浓度,分析比较各组临床资料,并进行随访.结果 组织因子浓度NSCLC组、良性肺病组均显著高于健康对照组[(550.88±201.58)、(510.77 ±201.20)、(178.34±66.73) ng/L,P均＜0.05].按组织因子水平分为低组织因子组(103.73～476.22 ng/L)和高组织因子组(476.22～1003.00 ng/L)后进行分析发现,NSCLC患者血浆组织因子水平随着肿瘤分期的升高而升高(P =0.026),且与肿瘤的远处转移明显相关(P =0.020).Kaplan-Meier生存分析(x2=0.145,P =0.704)、多因素Cox比例风险回归模型显示,组织因子表达水平与NSCLC预后无显著相关关系(RR=1.001,95％ CI0.998 ～1.004,P=0.452).结论 NSCLC患者组织因子水平与TNM分期有密切联系,与血栓栓塞性疾病的发生及生存率无明显相关,对NSCLC病情和预后的判断有局限性.
目的 檢測組織因子在非小細胞肺癌(NSCLC)患者血漿中的錶達,探討其與NSCLC患者高凝狀態、血栓栓塞性疾病及預後的關繫.方法 應用酶聯免疫吸附法檢測61例NSCLC患者、13例肺部良性疾病患者及14名健康對照者血漿組織因子濃度,分析比較各組臨床資料,併進行隨訪.結果 組織因子濃度NSCLC組、良性肺病組均顯著高于健康對照組[(550.88±201.58)、(510.77 ±201.20)、(178.34±66.73) ng/L,P均＜0.05].按組織因子水平分為低組織因子組(103.73～476.22 ng/L)和高組織因子組(476.22～1003.00 ng/L)後進行分析髮現,NSCLC患者血漿組織因子水平隨著腫瘤分期的升高而升高(P =0.026),且與腫瘤的遠處轉移明顯相關(P =0.020).Kaplan-Meier生存分析(x2=0.145,P =0.704)、多因素Cox比例風險迴歸模型顯示,組織因子錶達水平與NSCLC預後無顯著相關關繫(RR=1.001,95％ CI0.998 ～1.004,P=0.452).結論 NSCLC患者組織因子水平與TNM分期有密切聯繫,與血栓栓塞性疾病的髮生及生存率無明顯相關,對NSCLC病情和預後的判斷有跼限性.
목적 검측조직인자재비소세포폐암(NSCLC)환자혈장중적표체,탐토기여NSCLC환자고응상태、혈전전새성질병급예후적관계.방법 응용매련면역흡부법검측61례NSCLC환자、13례폐부량성질병환자급14명건강대조자혈장조직인자농도,분석비교각조림상자료,병진행수방.결과 조직인자농도NSCLC조、량성폐병조균현저고우건강대조조[(550.88±201.58)、(510.77 ±201.20)、(178.34±66.73) ng/L,P균＜0.05].안조직인자수평분위저조직인자조(103.73～476.22 ng/L)화고조직인자조(476.22～1003.00 ng/L)후진행분석발현,NSCLC환자혈장조직인자수평수착종류분기적승고이승고(P =0.026),차여종류적원처전이명현상관(P =0.020).Kaplan-Meier생존분석(x2=0.145,P =0.704)、다인소Cox비례풍험회귀모형현시,조직인자표체수평여NSCLC예후무현저상관관계(RR=1.001,95％ CI0.998 ～1.004,P=0.452).결론 NSCLC환자조직인자수평여TNM분기유밀절련계,여혈전전새성질병적발생급생존솔무명현상관,대NSCLC병정화예후적판단유국한성.
Objective To detect the plasma level of tissue factor (TF) in non-small cell lung cancer (NSCLC) patients,and to discuss its association with hypercoagulation,venous thromboembolism and prognosis of lung cancer.Methods Sixty-one impatients in our hospital with confirmed lung cancer were enrolled as the study group.Thirteen patients with benign pulmonary diseases and 14 healthy volunteers were selected as the control groups.Bseline and follow-up clinical data were collected from participants.Enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of TF in plasma of all subjects.Results The levels of TF in plasma from NSCLC patients and participants with benign pulmonary diseases was significantly higher than that in healthy controls((550.88 ± 201.58) ng/L vs (510.77 ± 201.20) ng/L vs (178.34 ±66.73) ng/L,P ＜0.05).According to the plasma levels of TF,which have been detected in all subjects,the patients were divided into two groups:low level group (range from 103.73 ng/L to 476.22 ng/L) and high level group (range from 476.221 ng/L to 1003.00 ng/L).Statistical analysis showed that there was a positive correlation between plasma TF levels and TNM stages in NSCLC patients (P =0.026).Patient with metastasis had a higher plasma TF level than other patients (P =0.020).The log-rank test revealed that there was no significant difference in survival between the high level group and low level group (x2 =0.145,P =0.704).Multivariate Cox proportional hazards regression analysis indicated that plasma TF levels did not predicted for death(RR =1.001,95％CI0.998-1.004,P=0.452).Conclusion The plasma TF level in NSCLC patients was correlated with TNM stages;it had no significant relationship with hypercoagulation state and survival rate in NSCLC patients.Limitations should be aware of while evaluating the clinical course and prediction of prognosis of NSCLC patients using plasma TF levels.
